ES2745704T3 - Células madre y células pancreáticas útiles para el tratamiento de diabetes mellitus insulinodependiente - Google Patents
Células madre y células pancreáticas útiles para el tratamiento de diabetes mellitus insulinodependiente Download PDFInfo
- Publication number
- ES2745704T3 ES2745704T3 ES13733516T ES13733516T ES2745704T3 ES 2745704 T3 ES2745704 T3 ES 2745704T3 ES 13733516 T ES13733516 T ES 13733516T ES 13733516 T ES13733516 T ES 13733516T ES 2745704 T3 ES2745704 T3 ES 2745704T3
- Authority
- ES
- Spain
- Prior art keywords
- cells
- pancreatic
- cell
- lineage
- reprogrammed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000004027 cell Anatomy 0.000 title claims abstract description 245
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 57
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 title claims abstract description 17
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 title description 2
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 52
- 230000008672 reprogramming Effects 0.000 claims abstract description 40
- 210000000496 pancreas Anatomy 0.000 claims abstract description 22
- 239000000203 mixture Substances 0.000 claims abstract description 16
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 15
- 239000013612 plasmid Substances 0.000 claims abstract description 15
- 230000008859 change Effects 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims description 38
- 230000004069 differentiation Effects 0.000 claims description 37
- 210000002966 serum Anatomy 0.000 claims description 12
- 210000005260 human cell Anatomy 0.000 claims description 9
- 230000002062 proliferating effect Effects 0.000 claims description 8
- 210000004923 pancreatic tissue Anatomy 0.000 claims description 6
- 230000009996 pancreatic endocrine effect Effects 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 4
- 101100239628 Danio rerio myca gene Proteins 0.000 claims description 3
- 108700021430 Kruppel-Like Factor 4 Proteins 0.000 claims description 3
- 101150039798 MYC gene Proteins 0.000 claims description 3
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 claims description 3
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 claims description 3
- 101100459258 Xenopus laevis myc-a gene Proteins 0.000 claims description 3
- 239000002609 medium Substances 0.000 description 24
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 20
- 230000014509 gene expression Effects 0.000 description 16
- 210000001778 pluripotent stem cell Anatomy 0.000 description 15
- 210000004413 cardiac myocyte Anatomy 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- 238000005516 engineering process Methods 0.000 description 12
- 102000004877 Insulin Human genes 0.000 description 10
- 108090001061 Insulin Proteins 0.000 description 10
- 229940125396 insulin Drugs 0.000 description 10
- 210000000056 organ Anatomy 0.000 description 10
- 102100028098 Homeobox protein Nkx-6.1 Human genes 0.000 description 9
- 101000578254 Homo sapiens Homeobox protein Nkx-6.1 Proteins 0.000 description 9
- 101710183548 Pyridoxal 5'-phosphate synthase subunit PdxS Proteins 0.000 description 9
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 9
- 230000001105 regulatory effect Effects 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 210000002242 embryoid body Anatomy 0.000 description 8
- 210000004153 islets of langerhan Anatomy 0.000 description 8
- 206010012601 diabetes mellitus Diseases 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 210000004940 nucleus Anatomy 0.000 description 7
- 210000001900 endoderm Anatomy 0.000 description 6
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 6
- 210000001161 mammalian embryo Anatomy 0.000 description 6
- 210000003716 mesoderm Anatomy 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 238000013459 approach Methods 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 238000011529 RT qPCR Methods 0.000 description 4
- 238000010009 beating Methods 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 210000003981 ectoderm Anatomy 0.000 description 4
- 238000003306 harvesting Methods 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 239000012581 transferrin Substances 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 3
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 3
- 102000008100 Human Serum Albumin Human genes 0.000 description 3
- 108091006905 Human Serum Albumin Proteins 0.000 description 3
- 108700020796 Oncogene Proteins 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 102000004338 Transferrin Human genes 0.000 description 3
- 108090000901 Transferrin Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000002124 endocrine Effects 0.000 description 3
- 210000001654 germ layer Anatomy 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 229960000890 hydrocortisone Drugs 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 230000003362 replicative effect Effects 0.000 description 3
- 229910052711 selenium Inorganic materials 0.000 description 3
- 239000011669 selenium Substances 0.000 description 3
- 229940091258 selenium supplement Drugs 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 102100028071 Fibroblast growth factor 7 Human genes 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- MIJPAVRNWPDMOR-ZAFYKAAXSA-N L-ascorbic acid 2-phosphate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(OP(O)(O)=O)=C1O MIJPAVRNWPDMOR-ZAFYKAAXSA-N 0.000 description 2
- 241000713869 Moloney murine leukemia virus Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102100032063 Neurogenic differentiation factor 1 Human genes 0.000 description 2
- 108050000588 Neurogenic differentiation factor 1 Proteins 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 238000010240 RT-PCR analysis Methods 0.000 description 2
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 102100035140 Vitronectin Human genes 0.000 description 2
- 108010031318 Vitronectin Proteins 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000004077 genetic alteration Effects 0.000 description 2
- 231100000118 genetic alteration Toxicity 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000000277 pancreatic duct Anatomy 0.000 description 2
- 210000003577 pancreatic endocrine progenitor Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical group C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- 229930183010 Amphotericin Natural products 0.000 description 1
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 101150059079 EBNA1 gene Proteins 0.000 description 1
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101001060261 Homo sapiens Fibroblast growth factor 7 Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 241000283923 Marmota monax Species 0.000 description 1
- 101100310648 Mus musculus Sox17 gene Proteins 0.000 description 1
- 108091057508 Myc family Proteins 0.000 description 1
- 101150114527 Nkx2-5 gene Proteins 0.000 description 1
- 102000019040 Nuclear Antigens Human genes 0.000 description 1
- 108010051791 Nuclear Antigens Proteins 0.000 description 1
- 206010033627 Pancreatic injury Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 244000000188 Vaccinium ovalifolium Species 0.000 description 1
- 108091093126 WHP Posttrascriptional Response Element Proteins 0.000 description 1
- 101100460507 Xenopus laevis nkx-2.5 gene Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 108010023082 activin A Proteins 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 229940009444 amphotericin Drugs 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008668 cellular reprogramming Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000013118 diabetic mouse model Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 108010007093 dispase Proteins 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000003890 endocrine cell Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 101150003286 gata4 gene Proteins 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 102000045246 noggin Human genes 0.000 description 1
- 108700007229 noggin Proteins 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000007388 punch biopsy Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000010907 stover Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0676—Pancreatic cells
- C12N5/0678—Stem cells; Progenitor cells; Precursor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/39—Pancreas; Islets of Langerhans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0676—Pancreatic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
- C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/42—Organic phosphate, e.g. beta glycerophosphate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/117—Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/385—Hormones with nuclear receptors of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/41—Hedgehog proteins; Cyclopamine (inhibitor)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1329—Cardiomyocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/22—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from pancreatic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Physiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nutrition Science (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261664259P | 2012-06-26 | 2012-06-26 | |
| PCT/US2013/047243 WO2014004341A1 (en) | 2012-06-26 | 2013-06-24 | Stem cells and pancreatic cells useful for the treatment of insulin-dependent diabetes mellitus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2745704T3 true ES2745704T3 (es) | 2020-03-03 |
Family
ID=48746139
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13733516T Active ES2745704T3 (es) | 2012-06-26 | 2013-06-24 | Células madre y células pancreáticas útiles para el tratamiento de diabetes mellitus insulinodependiente |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9968639B2 (enExample) |
| EP (2) | EP3611255A1 (enExample) |
| JP (2) | JP6386453B2 (enExample) |
| KR (2) | KR102058259B1 (enExample) |
| CN (2) | CN104640979B (enExample) |
| AU (2) | AU2013280698B2 (enExample) |
| BR (1) | BR112014031676A2 (enExample) |
| CA (1) | CA2876677C (enExample) |
| DK (1) | DK2864473T3 (enExample) |
| EA (2) | EA033954B1 (enExample) |
| ES (1) | ES2745704T3 (enExample) |
| IL (2) | IL236346B (enExample) |
| IN (1) | IN2015DN00281A (enExample) |
| PT (1) | PT2864473T (enExample) |
| SG (1) | SG11201408717XA (enExample) |
| WO (1) | WO2014004341A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106467918B (zh) * | 2015-08-18 | 2020-07-31 | 中国科学技术大学先进技术研究院 | 一种基于人皮肤细胞的胰岛素分泌细胞的诱导方法及应用 |
| CN105434471A (zh) * | 2015-11-26 | 2016-03-30 | 深圳爱生再生医学科技有限公司 | 治疗糖尿病的干细胞制剂及其制备方法 |
| WO2019157329A1 (en) * | 2018-02-09 | 2019-08-15 | Seraxis, Inc. | Pancreatic cells for treating diabetes and methods of generating the same |
| AU2019360857A1 (en) * | 2018-10-15 | 2021-06-03 | Evia Life Sciences Inc. | Method for producing stem/precursor cells, by using low molecular weight compound, from cells derived from endodermal tissue or organ |
| CN114845727B (zh) * | 2019-12-11 | 2025-08-26 | 国立大学法人东京大学 | 基于Mycl瞬时表达的可增殖性胰岛前体细胞样细胞的诱导和胰岛素阳性细胞的分化诱导 |
| US20220409855A1 (en) | 2021-06-29 | 2022-12-29 | Staffan Holmin | Methods of delivering cells and therapeutic agents to organs and extravascular sites |
| AU2023254488A1 (en) | 2022-04-15 | 2024-12-05 | Smartcella Solutions Ab | COMPOSITIONS AND METHODS FOR EXOSOME-MEDIATED DELIVERY OF mRNA AGENTS |
| EP4658761A1 (en) | 2023-02-03 | 2025-12-10 | Seraxis, Inc. | Therapeutic cells and methods relating to the same |
| WO2025029826A1 (en) | 2023-07-31 | 2025-02-06 | Seraxis, Inc. | Modified therapeutics cells and methods relating to the same |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5861313A (en) * | 1995-06-07 | 1999-01-19 | Ontogeny, Inc. | Method of isolating bile duct progenitor cells |
| EP1144631A3 (en) | 1999-01-07 | 2002-01-30 | Incyte Pharmaceuticals, Inc. | Insulin-synthesis genes |
| US6815203B1 (en) | 1999-06-23 | 2004-11-09 | Joslin Diabetes Center, Inc. | Methods of making pancreatic islet cells |
| US20030082155A1 (en) | 1999-12-06 | 2003-05-01 | Habener Joel F. | Stem cells of the islets of langerhans and their use in treating diabetes mellitus |
| EP1257282A4 (en) | 1999-12-06 | 2003-05-02 | Gen Hospital Corp | PANCREATIC STEM CELLS AND THEIR USE IN TRANSPLANTATION |
| US6436704B1 (en) | 2000-04-10 | 2002-08-20 | Raven Biotechnologies, Inc. | Human pancreatic epithelial progenitor cells and methods of isolation and use thereof |
| US7371576B2 (en) | 2002-09-06 | 2008-05-13 | Reneuron, Inc. | CD56 positive human adult pancreatic endocrine progenitor cells |
| PT1636348E (pt) | 2003-06-20 | 2009-10-21 | Vrije Universiteit Brussel Vub | Método de gerar ilhotas de células beta a partir de células pancreáticas exócrinas |
| WO2005086860A2 (en) * | 2004-03-09 | 2005-09-22 | Gang Xu | Methods for generating insulin-producing cells |
| US20060029987A1 (en) | 2004-08-06 | 2006-02-09 | Applera Corporation | Diagnosis of pancreatic cancer by using pancreatic targets |
| US7807459B2 (en) | 2005-09-27 | 2010-10-05 | Reneuron, Inc. | EphA4-positive human adult pancreatic endocrine progenitor cells |
| US20100137202A1 (en) * | 2006-07-19 | 2010-06-03 | University Of Florida Research Foundation | Compositions for reprogramming a cell and uses therefor |
| US20100204258A1 (en) | 2007-03-12 | 2010-08-12 | The Trustees Of Columbia University In The City Of New York | Methods and compositions for modulating insulin secretion and glucose metabolism |
| WO2009061024A1 (en) | 2007-11-09 | 2009-05-14 | Rnl Bio Co., Ltd | Method for isolating and culturing adult stem cells derived from human amniotic epithelium |
| US8470595B2 (en) | 2008-04-18 | 2013-06-25 | National University Corporation Nagoya University | Mesenchymal stem cell and method for production thereof |
| JP2011519574A (ja) * | 2008-05-09 | 2011-07-14 | ザ ユニバーシティ コート オブ ザ ユニバーシティ オブ グラスゴー | 細胞ベースの治療に関連する材料および方法 |
| WO2010022395A2 (en) * | 2008-08-22 | 2010-02-25 | President And Fellows Of Harvard College | Methods of reprogramming cells |
| AU2009329893A1 (en) * | 2008-12-23 | 2011-06-30 | Vivoscript, Inc. | Compositions and methods for re-programming cells without genetic modification |
| US20120263689A1 (en) * | 2009-09-10 | 2012-10-18 | The Salk Institute For Biological Studies | Adipose-derived induced pluripotent stem cells |
| RU2663339C1 (ru) * | 2010-05-12 | 2018-08-03 | Янссен Байотек, Инк. | Дифференцирование эмбриональных стволовых клеток человека |
| WO2012025914A1 (en) * | 2010-08-22 | 2012-03-01 | Ramot At Tel-Aviv University Ltd. | Induced pluripotent stem cells derived from human pancreatic beta cells |
| JP6133776B2 (ja) * | 2010-08-31 | 2017-05-24 | ヤンセン バイオテツク，インコーポレーテツド | 多能性幹細胞の分化 |
| WO2012035539A1 (en) * | 2010-09-15 | 2012-03-22 | Ramot At Tel-Aviv University Ltd. | Methods of expanding and redifferentiating islet beta cells |
| US20120135015A1 (en) * | 2010-09-28 | 2012-05-31 | Baylor Research Institute | Induction of Pancreatic Stem Cells by Transient Overexpression of Reprogramming Factors and PDX1 Selection |
-
2013
- 2013-06-24 KR KR1020157000845A patent/KR102058259B1/ko active Active
- 2013-06-24 PT PT13733516T patent/PT2864473T/pt unknown
- 2013-06-24 CN CN201380033028.9A patent/CN104640979B/zh active Active
- 2013-06-24 ES ES13733516T patent/ES2745704T3/es active Active
- 2013-06-24 DK DK13733516.2T patent/DK2864473T3/da active
- 2013-06-24 CA CA2876677A patent/CA2876677C/en active Active
- 2013-06-24 SG SG11201408717XA patent/SG11201408717XA/en unknown
- 2013-06-24 JP JP2015520349A patent/JP6386453B2/ja active Active
- 2013-06-24 EA EA201590088A patent/EA033954B1/ru not_active IP Right Cessation
- 2013-06-24 WO PCT/US2013/047243 patent/WO2014004341A1/en not_active Ceased
- 2013-06-24 KR KR1020197036838A patent/KR102174581B1/ko active Active
- 2013-06-24 EP EP19185702.8A patent/EP3611255A1/en active Pending
- 2013-06-24 BR BR112014031676A patent/BR112014031676A2/pt not_active Application Discontinuation
- 2013-06-24 CN CN202110419726.9A patent/CN113265370A/zh active Pending
- 2013-06-24 EA EA201992135A patent/EA201992135A1/ru unknown
- 2013-06-24 AU AU2013280698A patent/AU2013280698B2/en active Active
- 2013-06-24 EP EP13733516.2A patent/EP2864473B1/en active Active
- 2013-06-24 US US13/925,248 patent/US9968639B2/en active Active
-
2014
- 2014-12-18 IL IL236346A patent/IL236346B/en active IP Right Grant
-
2015
- 2015-01-13 IN IN281DEN2015 patent/IN2015DN00281A/en unknown
- 2015-04-22 US US14/693,245 patent/US9474772B2/en active Active
-
2018
- 2018-08-09 JP JP2018149816A patent/JP6856586B2/ja active Active
-
2019
- 2019-03-26 AU AU2019202085A patent/AU2019202085A1/en not_active Abandoned
- 2019-05-28 IL IL266965A patent/IL266965B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2745704T3 (es) | Células madre y células pancreáticas útiles para el tratamiento de diabetes mellitus insulinodependiente | |
| KR102210850B1 (ko) | 비-다능성 세포를 다능성 줄기 세포가 되도록 재프로그래밍하기 위한 조성물 및 방법 | |
| US9926532B2 (en) | Method of generating induced pluripotent stem cells and differentiated cells | |
| JP6581655B2 (ja) | 多能性幹細胞由来ケラチノサイトの生成およびケラチノサイト培養の維持 | |
| US20120282229A1 (en) | Non-viral delivery of transcription factors that reprogram human somatic cells into a stem cell-like state | |
| CN102144027B (zh) | 生产多能干细胞的方法 | |
| CN113015794A (zh) | 包含用于条件性永生化的可控转基因的诱导多能细胞 | |
| Hu et al. | Derivation, expansion, and motor neuron differentiation of human-induced pluripotent stem cells with non-integrating episomal vectors and a defined xenogeneic-free culture system | |
| CN117321190A (zh) | 包含用于条件性永生化的可控转基因的诱导多能细胞 | |
| EP2481795A1 (en) | Method of generating induced pluripotent stem cells and differentiated cells | |
| JP2014523744A (ja) | 多能性幹細胞を得るための細胞抽出物の使用 | |
| US20220333070A1 (en) | Induction of functional astrocytes from pluripotent stem cells | |
| EA045078B1 (ru) | Стволовые клетки и клетки поджелудочной железы, используемые для лечения инсулинозависимого сахарного диабета | |
| Pisal | Cellular Reprogramming as a Tool for Harvesting Patient-specific Stem Cells | |
| Li et al. | AUTHOR COPY ONLY |